Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma

Krishna A J Mutgi; Mohammed Milhem; Brian L Swick; Vincent Liu

doi:10.1016/j.jdcr.2016.06.012

Back

Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma

Journal article

Open access

Peer reviewed

Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma

Krishna A J Mutgi, Mohammed Milhem, Brian L Swick and Vincent Liu

JAAD Case Reports, Vol.2(4), pp.343-345

08/17/2016

DOI: 10.1016/j.jdcr.2016.06.012

PMCID: PMC4992012

PMID: 27570820

Files and links (2)

pdf

Pityriasis lichenoides chronica-like drug eruption developing dur706.33 kBDownload View

Published (Version of record)CC BY-NC-ND V4.0, Open Access

url

https://doi.org/10.1016/j.jdcr.2016.06.012View

Published (Version of record)JAAD Case Reports, Volume 2, Issue 4, July 2016, Pages 343–345.

Abstract

Introduction: Immune checkpoint inhibitors such as ipilimumab (anticytotoxic T-lymphocyte–associated antigen), pembrolizumab, and nivolumab (anti–programmed death receptor represent some of the newest and most promising medications for the treatment of metastatic melanoma. As a class, immune checkpoint inhibitors interfere with tumoral suppression of T cells, resulting in a more robust immune response and subsequent benefit in the treatment of melanoma, non–small-cell lung cancer, and potentially other malignancies. Unfortunately, immune checkpoint inhibitors also interfere with suppression of autoimmunity, and several immune-related adverse events have been attributed to these medications. Patients receiving programmed death receptor 1 (PD-1) inhibitors have had morbilliform eruptions, vitiligo, pruritus, neutrophilic dermatosis, lichen planus, psoriasis, bullous erythema multiforme, Stevens-Johnson syndrome, and bullous pemphigoid. Here we present a novel case of a pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab therapy.

Dermatology

Oncology

OAfund

pembrolizumab

pityriasis lichenoides chronica

programmed death receptor 1

PD-1

Details

Title: Subtitle: Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma
Creators: Krishna A J Mutgi - University of Iowa
Mohammed Milhem - University of Iowa
Brian L Swick - University of Iowa
Vincent Liu - University of Iowa
Resource Type: Journal article
Publication Details: JAAD Case Reports, Vol.2(4), pp.343-345
DOI: 10.1016/j.jdcr.2016.06.012
PMID: 27570820
PMCID: PMC4992012
ISSN: 2352-5126
Language: English
Date published: 08/17/2016
Academic Unit: Internal Medicine; Orthopedics and Rehabilitation; Dermatology; Pathology
Record Identifier: 9983557569202771

Metrics

127 File views/ downloads

45 Record Views

See more details